This clinical trial is focused on studying treatments for elderly patients with a type of cancer called Diffuse Large B-Cell Lymphoma (DLBCL) and another type called Follicular Lymphoma grade IIIb (FL3B). The study will use a medication called prednisone, which is a synthetic glucocorticoid, and may also include a supplement known as Vitamin D (also referred to as colecalciferol). The purpose of the study is to see if adding Vitamin D to the treatment with prednisone can improve the time patients live without the disease getting worse, known as progression-free survival.
Participants in the study will receive a pre-treatment phase with oral prednisone, with some also receiving Vitamin D supplementation. This will be followed by six cycles of a standard cancer treatment called immunochemotherapy. The study is designed to compare the outcomes of those who receive Vitamin D with those who do not, to determine if the addition of Vitamin D provides any benefits in managing the disease.
The trial is open-label, meaning both the researchers and participants know which treatments are being administered. It is a randomized study, so participants will be randomly assigned to either receive Vitamin D with prednisone or prednisone alone. The study aims to provide valuable information on whether Vitamin D can enhance the effectiveness of the treatment for elderly patients with DLBCL and FL3B.
Italy 
